Mocht u kanker-actueel de moeite waard vinden en ons willen ondersteunen om kanker-actueel online te houden dan kunt u ons machtigen voor een periodieke donatie via donaties: https://kanker-actueel.nl/NL/donaties.html of doneer al of niet anoniem op - rekeningnummer NL79 RABO 0372931138 t.n.v. Stichting Gezondheid Actueel in Amersfoort. Onze IBANcode is NL79 RABO 0372 9311 38   
 Elk bedrag is welkom. En we zijn een ANBI instelling dus uw donatie of gift is in principe aftrekbaar voor de belasting.

En als donateur kunt u ook korting krijgen bij verschillende bedrijven: 

https://kanker-actueel.nl/NL/voordelen-van-ops-lidmaatschap-op-een-rijtje-gezet-inclusief-hoe-het-kookboek-en-de-recepten-op-basis-van-uitgangspunten-van-houtsmullerdieet-te-downloaden-enof-in-te-zien.html

20 augustus 2017: lees ook dit artikel: 

https://kanker-actueel.nl/NL/arsenic-trioxide-intraveneus-in-combinatie-met-tace-geeft-veel-betere-resultaten-voor-in-longen-uitgezaaide-gevorderde-primaire-leverkanker-dan-tace-alleen.html

27 mei 2016: lees ook dit artikel over hetzelfde onderwerp: 

https://kanker-actueel.nl/NL/arsenicum-trioxide-ato-geeft-significant-betere-resultaten-naast-tace-bij-patienten-met-primaire-leverkanker-met-longuitzaaiingen.html

27 mei 2016: Bron: CANCER: Version of Record online: 29 MAY 2015 DOI: 10.1002/cncr.29456

Ook deze studie (aanvullend op onderstaande studiepublicatie uit maart 2015) geeft heel goede resultaten van arsenicum trioxide gebruikt in loco regionale behandeling met leverspoelingen (o.a. TACE) van vergevorderde primaire leverkanker. Meer dan de helft van de patienten uit de groep van arsenicum triode overleefde de 25 maanden studiefollow-up: 15 patienten van de 61 overleden in de arsenicum trioxidegroep versus 34 patienten uit 64 patienten uit de controlegroep. Een onvoorstelbaar groot verschil voor een groep patienten die inoperabele leverkanker hadden en zwaar waren voorbehandeld.

Het volledige studierapport: Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma. is gratis in te zien met duidlejik grafieken enz. Onder dit artikel staat het abstract ervan.

Hier een van de grafieken uit bovenstaande studie. daaronder beschrijving van andere studie

Arsenicum trioxide studie bij TACE en leverkanker


23 november 2015: lees ook dit artikel: 

https://kanker-actueel.nl/NL/tace-plus-gemoduleerd-virus-adenovirus-h101-verbetert-significant-ziektevrije-tijd-en-overall-overleving-plus-16-procent-in-vergelijking-met-alleen-tace-bij-inoperabele-primaire-leverkanker-stadium-4.html

19 maart 2015: Bron: J Cancer Res Clin Oncol. 2014 Dec 14. [Epub ahead of print]

Wanneer TACE - Trans Arteriële Chemo Embolisatie wordt uitgevoerd met Arseentrioxide bij primaire leverkanker met uitzaaiingen in de longen en de patiënten aanvullend daarna regelmatig intraveneuze injecties krijgen met ATO - arseentrioxide dan stijgt de mediane overleving van 2,9 maanden naar 7,3 maanden en blijkt de ziektecontrole maar liefst met 65% te verbeteren van 72,8% versus 7,2% in vergelijking met alleen TACE plus arseentrioxide. Een spectaculaire verbetering dus. Je zou je ook nog af kunnen vragen wat er gaat gebeuren als ATO intraveneus wordt vervangen / uitgebreid door ATRA - All-trans-Retionic-Acid. Of simpeler in het Nederlands een vorm van vitamine A plus kleine dosis arsenicum. Zie o.a. deze studie: 

https://kanker-actueel.nl/NL/acute-promyelocitische-leukemie-apl-volledig-te-genezen-met-niet-toxische-aanpak-van-all-trans-retinoic-acid-atra-en-arseentrioxide-ato-en-zonder-chemo.html 

Met, ik citeer wat Francesco Lo-Coco, MD, professor in de hematologie aan de universiteit van Tor Vergata in Rome, Italië zei. Heel opmerkelijk aan deze studie is dat volgens dr. Lo-Coco  het bewijs geleverd wordt dat het mogelijk is kwaadaardige kankercellen (met ATRA)  te transformeren in normale cellen zonder deze te doden met chemotherapie.  "Kanker is blijkbaar geen onomkeerbare toestand".

Blijkbaar werkt ATRA als een anti-PD middel. Is heel wat goedkoper dan bv. nivolumab, wat overigens ook spectaculaire resultaten laat zien bij verschillende vormen van kanker, waaronder bij melanomen: 

https://kanker-actueel.nl/NL/immuuntherapeutische-behandelingen-met-ipilimumab-en-nivolumab-gelijktijdig-gegeven-geeft-spectaculaire-resultaten-80-procent-tumorreductie-bij-melanoompatienten-met-uitgezaaide-vergevorderde-vooraf-intensief-behandelde-ziekte.html

en bij darmkanker loopt al een fase III studie in verschillende Europese landen waaronder ook Nederland: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000095-42/NL.

Arseentrioxide

De nieuwste studie publicatie geeft deze resultaten:

RESULTATEN:

Tussen April 2013 en June 2014, kregen 139 patienten de TACE - behandeling. 70 van hun namen deel aan de studiegroep TACE met ATO plus daarna intraveneus ATO en 69 van hun vormden de controlegroep: TACE + ATO maar zonder intraveneuze ATO. Alle patienten konden de volledige behandeling volgens het studieprotocol volgen, niemand haakte af tijdens de studieduur.

De mediane overall overleving was 7.3 maanden (95 % CI = 6.8-7.8) in de studiegroep van TACE + ATO + ATO intraveneus en 2.9 maanden (95 % CI = 2.6-3.1) in de controlegroep met alleen TACE + ATO.  Dit was statistisch significant (P < 0.001). De mediane progressie vrije tijd (TTP) was 2.7 maanden (95 % CI = 1.9-3.3) voor de studiegroep van TACE + ATO + ATO intraveneus en 1.2 (95 % CI = 1.0-1.9) maanden in de controle groep (P = 0.023). Ziektecontrole DCR - Disease Control) bleek in de studiegroep van TACE + ATO + ATO intraveneus 72.85 % versus 7,24% in de controlegroep. En de onafhankelijke vastgestelde respons (ORR - objective response rate) was 7.14 %, tegenover in de controlegroep 0.00 %. DCR - ziektecontrole en ORR - onafhankelijke respons gaven dus een significant verschil te zien tussen de twee groepen (P < 0.001 en P = 0.024, respectievelijk).

Het volledige studierapport: Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial. kunt u tegen betaling inzien.

Hier het abstract van de studie:

Arsenic trioxide transarterial chemoembolization and intravenous administration were safe and effective in unresectable hepatocellular carcinoma with lung metastasis.

Date: 14 Dec 2014

Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial

Abstract

Aim

To evaluate the efficacy and safety of arsenic trioxide transarterial chemoembolization and intravenous administration in unresectable hepatocellular carcinoma with lung metastasis.

Methods

A single-blind, two-parallel group, randomized trial was conducted at three medical centers (Guangzhou, China), including patients with both biopsy-confirmed hepatocellular carcinoma and lung metastasis. The experimental group received arsenic trioxide transarterial chemoembolization and intravenous administration of arsenic trioxide, while the control group only received arsenic trioxide transarterial chemoembolization. We compared overall survival (OS), time to progression (TTP), disease control rate (DCR), and objective response rate (ORR) between the groups.

Results

Between April 2013 and June 2014, 139 patients received the allocated intervention, 70 of whom were in the experimental group and 69 of whom were in the control group. No patient was lost to follow-up. The median OS was 7.3 (95 % CI = 6.8–7.8) months in the experimental group and 2.9 (95 % CI = 2.6–3.1) months in the control group (P < 0.001). The median TTP was 2.7 (95 % CI = 1.9–3.3) months in the experimental group and 1.2 (95 % CI = 1.0–1.9) months in the control group (P = 0.023). In the experimental group, the DCR was 72.85 % and the ORR was 7.14 %, while in the control group, the DCR was 7.24 % and the ORR was 0.00 %. DCR and ORR differed significantly between the two groups (P < 0.001 and P = 0.024, respectively).

Conclusions

Arsenic trioxide transarterial chemoembolization and intravenous administration were safe and effective in unresectable hepatocellular carcinoma with lung metastasis.

References:

  1. Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, Surico N, Malavasi F, Ferrero E (2002) Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 1:71–73 CrossRef
  2. Cabrera R, Nelson DR (2010) Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 31(4):461–476 CrossRef
  3. Chen GQ, Shi XG, Tang W et al (1997) Use of arsenic trioxide (arsenic trioxide) in the treatment of acute promyelocytic leukemia (APL): I. Arsenic Trioxide exerts dose-dependent dual effects on APL cells. Blood 89(9):3345–3353
  4. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34 CrossRef
  5. Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247 CrossRef
  6. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA et al (2010) Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 44:239–245 CrossRef
  7. Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH (2007) Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Investig New Drugs 1:77–84
  8. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390 CrossRef
  9. Maeda H, Hori S, Nishitoh H et al (2001) Tumor growth inhibition by arsenic trioxide (arsenic trioxide) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 61(14):5432–5440
  10. Moon Y, Park G, Kim Y et al (2004) Arsenic trioxide (arsenic trioxide) sensitivity of carcinoma cell lines and cancer cells from patients with carcinomatosis peritonei. Ann Clin Lab Sci 34(3):271–276
  11. Oketani M, Kohara K, Tuvdendorj D et al (2001) Inhibition by arsenic trioxide of human hepatoma cell growth. Cancer Lett 183:147–153 CrossRef
  12. Parkin DM, Bray F, Ferlay J, Pisani P (2000) Estimating the world cancer burden: globocan. Int J Cancer 94(2001):153–156
  13. Qian J (2011) Interventional therapies of unresectable liver metastases. J Cancer Res Clin Oncol 137(12):1763–1772 CrossRef
  14. Shindoh J et al (2013) Risk factors of post-operative recurrence and adequate surgical approach to improve long-term outcomes of hepatocellular carcinoma. HPB (Oxford) 15(1):31–39 CrossRef
  15. Vuky J, Yu R, Schwartz L, Motzer RJ (2002) Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Investig New Drugs 20(3):327–330 CrossRef
  16. Wu XZ, Xie GR (2008) Induced differentiation of hepatocellular carcinoma by natural products. Afr J Tradit Complement Altern Med 5(4):325–331
  17. Yu J, Qian H, Li Y et al (2007) Therapeutic effect of arsenic trioxide (arsenic trioxide) on cervical cancer in vitro and in vivo through apoptosis induction. Cancer Biol Ther 6(4):580–586 CrossRef
  18. Zhang P, Zhao Y (2010) Tumor biology and tumor load on effects of prognosis of colorectal cancer liver metastases liver resection treatment. J Hepatobiliary Surg 3:234

Locoregional therapy combined with arsenic trioxide prevents extrahepatic metastasis and prolongs the survival time for primary HCC patients

Cancer. 2015 Sep 1;121(17):2917-25. doi: 10.1002/cncr.29456. Epub 2015 May 29.

Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma.

Wang H1, Liu Y1, Wang X1, Liu D1, Sun Z1, Wang C1, Jin G1, Zhang B1, Yu S1.

Author information

Abstract

BACKGROUND:

The objective of this study was to determine the efficacy and safety of locoregional therapy (LRT) combined with arsenic trioxide (As2 O3 ) treatment in primary hepatocellular carcinoma (HCC) patients.

METHODS:

One hundred twenty-five primary HCC patients were recruited for a randomized controlled study. Patients were randomly divided into group A (n = 61) and group B (n = 64). All patients received transarterial chemoembolization. Group A patients were given As2 O3 at 10 mg/d for 4 courses (21 days per course) with a 2-week interval between courses. Survival times, therapeutic responses, extrahepatic metastases, and adverse events were recorded.

RESULTS:

A better therapeutic response was found in group A patients, as shown by higher objective response rate (ORR) and clinical benefit rate (CBR) values in group A versus group B (ORR, 81.96% [95% confidence interval (CI), 72.32%-91.62%] vs 59.37% [95% CI, 47.34%-71.41%], χ(2)  = 7.650, P < .05; CBR, 95.08% [95% CI, 89.66%-100.00%] vs 81.25% [95% CI, 71.69%-90.81%], χ(2)  = 5.659, P < .05). There were fewer patients with extrahepatic metastases in group A versus group B (group A, 6 cases or 9.84% [95% CI, 2.36%-17.31%]; group B, 12 cases or 18.75% [95% CI, 9.19%-28.31%]). The survival rate for group A patients was significantly higher than that for group B patients (P < .05). No significant differences were found between the 2 groups in terms of hematology or digestive system, liver, or kidney dysfunction except for facial and limb edema.

CONCLUSIONS:

LRT combined with As2 O3 treatment prevents extrahepatic metastasis and prolongs the survival time for primary HCC patients.

© 2015 American Cancer Society.

REFERENCES

  • 1
    Garcia M, Jemal A, Ward EM, et al. Global cancer facts and figure 2007. Atlanta, GA:America Cancer Society. 2007;2-3.
  • 2
    Abdel-Rahman O. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside. J Egypt Natl Canc Inst. 2013;25:165-171.
  • 3
    Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-1739.
  • 4
    Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-1171.
    Direct Link:
  • 5
    Wang P, Sheng L, Wang G, et al. Association of transarterial chemoembolization with survival in patients with unresectable hepatocellular carcinoma. Mol Clin Oncol. 2014;2:203-206.
  • 6
    Meng MB, Cui YL, Lu Y, et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol. 2009;92:184-194.
  • 7
    Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int. 2010;30:741-749.
    Direct Link:
  • 8
    Seki T, Tamai T, Nakagawa T, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer. 2000;89:1245-1251.
    Direct Link:
  • 9
    Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J. Cancer: a systems biology disease. Biosystems. 2006;83:81-90.
  • 10
    Bruix J, Takayama T, Mazzaferro V. STORM: a phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC) [ASCO abstract 4006]. J Clin Oncol. 2014;32:5s.
  • 11
    Zhang W, Sun HC, Wang WQ, et al. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice. Gastroenterology. 2012;143:1641-1649.
  • 12
    Watts JM, Tallman MS. Acute promyelocytic leukemia: what is the new standard of care? Blood Rev. 2014;28:205-212.
  • 13
    Tan B, Huang JF, Wei Q, Zhang H, Ni RZ. Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in rats. World J Gastroenterol. 2005;11:5938-5943.
  • 14
    Xu HY, Yang YL, Liu SM, Bi L, Chen SX. Effect of arsenic trioxide on human hepatocarcinoma in nude mice. World J Gastroenterol. 2004;10:3677-3679.
  • 15
    Kakumu S. Trends in liver cancer researched by the Liver Cancer Study Group of Japan. Hepatol Res. 2002;24(suppl):21-27.
  • 16
    Ikai I, Itai Y, Okita K. Report of the 15th follow-up survey of primary liver cancer. Hepatol Res. 2004;28:21-29.
  • 17
    Kofinek V, Barker N, Morerer P, et al. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet. 1998;19:379-383.
  • 18
    Zhang XP, Zheng G, Zou L, et al. Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells. Mol Cell Biochem. 2008;307:101-108.
  • 19
    Robey RW, Polgar O, Deeken J, et al. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007;26:39-57.
  • 20
    Robey RW, Shakla S, Finley EM, et al. Inhibition of P-glycoprotein (ABCB1) and multidrug resistance associated protein 1 (ABCC1) mediated transport by the orally administered inhibitor, CBT-1(R). Biochem Pharmacol. 2008;75:1302-1312.
  • 21
    Yang ZF, Ngai P, Ho DW, et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology. 2008;47:919-928.
    Direct Link:
  • 22
    Ciprian T, Olga S, Dan Rus-Ciuca, et al. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. J Gastrointestin Liver Dis. 2010;19:61-67.
  • 23
    Oishi N, Wang XW. Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci. 2011;7:517-535.
  • 24
    Sang HK, In CP, Myung JP, et al. Arsenic trioxide sensitizes CD95/Fas-induced apoptosis through ROS-mediated upregulation of CD95/Fas by NF-kB activation. Int J Cancer. 2004;112:596-606.
    Direct Link:
  • 25
    Christian S, Antje R, Mario L, et al. Arsenic trioxide induces regulated, death receptor–independent cell death through a Bcl-2–controlled pathway. Oncogene. 2005;24:7031-7042.
  • 26
    Oketani M, Kohara K, Tuvdendorj D, et al. Inhibition by arsenic trioxide of human hepatoma cell growth. Cancer Lett. 2002;183:147-153.
  • 27
    Fei M, Lu M, Wang Y, et al. Arsenic trioxide–induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization. Med Oncol. 2008;26:178-185.
  • 28
    Liu ZM, Tseng JT, Hong DY, et al. Suppression of TG-interacting factor sensitizes arsenic trioxide–induced apoptosis in human hepatocellular carcinoma cells. Biochem J. 2011;438:349-358.
  • 29
    Meng XZ, Zheng TS, Chen X, et al. MicroRNA expression alteration after arsenic trioxide treatment in HepG-2 cells. J Gastroenterol Hepatol. 2011;26:186-193.
    Direct Link:
  • 30
    Li H, Gong J, Jiang X, Shao H. Arsenic trioxide treatment of rabbit liver VX-2 carcinoma via hepatic arterial cannulation–induced apoptosis and decreased levels of survivin in the tumor tissue. Croat Med J. 2013;54:12-16.
  • 31
    Shen P, Jiang T, Lu H, Han H, Luo R. Combination of poly I:C and arsenic trioxide triggers apoptosis synergistically via activation of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells. Cell Biol Int. 2011;35:803-810.
    Direct Link:
  • 32
    Ling YH, Jiang JD, Holland JF. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis human tumor cell lines. Mol Pharmacol. 2002;62:529-538.
  • 33
    Pelicano H, Feng L, Zhou Y, et al. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem. 2003;278:37832-37839.
  • 34
    Nutt LK, Gogvadze V, Uthaisang W, Mirnikjoo B, McConkey DJ, Orrenius S. Indirect effects of Bax and Bak initiate the mitochondrial alterations that lead to cytochrome c release during arsenic trioxide–induced apoptosis. Cancer Biol Ther. 2005;4:459-467.
  • 35
    Alarifi S, Ali D, Alkahtani S, Siddiqui MA, Ali BA. Arsenic trioxide–mediated oxidative stress and genotoxicity in human hepatocellular carcinoma cells. Onco Targets Ther. 2013;6:75-84.
  • 36
    Seong NJ, Yoon CJ, Kang SG, Chung JW, Kim HC, Park JH. Effects of arsenic trioxide on radiofrequency ablation of VX2 liver tumor: intraarterial versus intravenous administration. Korean J Radiol. 2012;13:195-201.
  • 37
    Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res. 1999;59:6033-6037.
  • 38
    Tomuleasa C, Soritau O, Fischer-Fodor E, et al. Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. Hematol Oncol Stem Cell Ther. 2011;4:60-66.
  • 39
    Zhang KZ, Zhang QB, Sun HC, et al. Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model. J Hematol Oncol. 2014;7:28.
  • 40
    Qu FL, Hao XZ, Qin SK, et al. Multicenter phase II clinical trial of arsenic trioxide injection in the treatment of primary hepatocarcinoma [in Chinese]. Zhonghua Zhong Liu Za Zhi. 2011;33:697-701.
  • 41
    Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH. Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs. 2007;25:77-84.
  • 42
    Meng YL, Hu HT, Li HL, et al. The clinical therapeutic effects of arsenic trioxide combined with transcatheter arterial chemoembolization in treating primary liver cancer with pulmonary metastases [in Chinese]. Zhonghua Nei Ke Za Zhi. 2012;51:971-974.
  • 43
    Wang GZ, Zhang W, Fang ZT, et al. Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro. J Cancer Res Clin Oncol. 2014;140:1125-1136.
  • 44
    Garcia M, Jemal A, Ward EM, et al. Global cancer facts and figure. Atlanta, GA: America Cancer Society. 2007;2–3.

TACE - Trans Arteriele Chemo Embolisatie, ATRA - all-trans-retinoic acid, ATO - arsenicum trioxide, arseentrioxide, primaire leverkanker, longuitzaaiingen, leverkanker, levertumoren


Plaats een reactie ...

Reageer op "TACE met ATO - Arseentrioxide plus intraveneuze injecties met arseentrioxide zorgt bij primaire leverkanker met uitzaaiingen in de longen voor langere overleving - 7.3 vs 2.9 maanden - en 65 procent betere ziektecontrole"


Gerelateerde artikelen
 

Gerelateerde artikelen

TACE met lokaal hyperthermie >> TCM in de vorm van de Fuzheng >> Arsenic trioxide intraveneus >> TACE plus gemoduleerd virus >> TACE met ATO - Arseentrioxide >> Arsenicum trioxide (ATO) geeft >> Leverkanker: Tace - Trans >> Leverkanker: TACE in combinatie >> Leverkanker: TACE - Trans >> Ethanol: TACE - Transarteriële >>